Abstract

Background In recent years, the incidence of colorectal cancer (CRC) has continued to increase. Although the overall prognosis of CRC has improved with the continuous improvement of the level of treatment, the prognosis of metastatic colorectal cancer (mCRC) is still poor. The purpose of our study is to explore the prognostic value of platelet to lymphocyte ratio (PLR) in mCRC. Methods The PubMed, Web of Science, and Embase (via OVID) were systematically searched to obtain all relevant research. We used hazard ratio (HR) with 95% confidence interval (CI) to assess the associations of PLR and overall survival (OS) and progression free survival (PFS). Results A total of twelve studies containing 1452 patients were included in this meta-analysis. Pooled analysis showed that high levels of PLR were associated with poor OS (HR: 1.72, 95% CI: 1.27–2.33, and P < 0.01) and PFS (HR: 1.64, 95% CI: 1.16–2.31, and P = 0.033). Conclusion Our analysis suggested that high levels of PLR pretreatment may be an effective predictive biomarker for the prognosis of mCRC patients.

Highlights

  • Colorectal cancer (CRC) is one of the most common malignant tumors in the world

  • This meta-analysis combined the results of 1452 patients with metastatic colorectal cancer (mCRC) from 12 individual studies; we reassessed the prognostic role of platelet to lymphocyte ratio (PLR) in mCRC

  • We conducted a subgroup analysis to assess the prognostic significance of PLR, and the results showed that the prediction of PLR for overall survival (OS) is meaningful in all subsets

Read more

Summary

Introduction

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. The prognosis of patients with metastatic colorectal cancer (mCRC) is still poor, and the median overall survival (OS) is about 30 months [5]. The incidence of colorectal cancer (CRC) has continued to increase. The overall prognosis of CRC has improved with the continuous improvement of the level of treatment, the prognosis of metastatic colorectal cancer (mCRC) is still poor. Pooled analysis showed that high levels of PLR were associated with poor OS (HR: 1.72, 95% CI: 1.27–2.33, and P < 0:01) and PFS (HR: 1.64, 95% CI: 1.16–2.31, and P = 0:033). Our analysis suggested that high levels of PLR pretreatment may be an effective predictive biomarker for the prognosis of mCRC patients

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.